BRIEF—Xarelto reimbursement confirmed in UK

The UK’s reimbursement agency has made final its recommendation, announced in August 2019, that Bayer’s Xarelto (rivaroxaban) should be available through the country’s National Health Service (NHS).

The option, which is marketed by J&J in the USA, will be funded for regular use on the NHS, for preventing atherothrombotic events in certain adults with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD).

Lars Bruening, CEO Bayer UK & Ireland, said: “Ten years on from the introduction of rivaroxaban into the UK we are continuing to see the enduring impact that it has on patients treated across its licensed indications – and now this new patient population with previous unmet needs can be considered.”